MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on February 9, 2007; DOI: 10.1124/mol.106.031617


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.031617v1
71/5/1369    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciccarelli, R.
Right arrow Articles by Caciagli, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciccarelli, R.
Right arrow Articles by Caciagli, F.


Received for publication October 12, 2006.
Revised January 29, 2007.
Accepted for publication February 9, 2007.

Molecular signalling mediating the protective effect of A1 adenosine and mGlu3 metabotropic glutamate receptor activation against apoptosis by oxygen/glucose deprivation in cultured astrocytes

Renata Ciccarelli 1*, Iolanda D'Alimonte 1, Patrizia Ballerini 1, Mariagrazia D'Auro 1, Eleonora Nargi 1, Silvana Buccella 1, Patrizia Di Iorio 1, Valeria Bruno 2, Ferdinando Nicoletti 2, Francesco Caciagli 1

1 Department of Biomedical Sciences. University of Chieti 2 Dept. of Human Physiology and Pharmacology. University of Rome

* Address correspondence to: E-mail: r.ciccarelli{at}dsb.unich.it

Abstract

Astrocyte death may occur in neurodegenerative disorders, and complicates the outcome of brain ischemia, a condition associated with high extracellular levels of adenosine and glutamate. We show that pharmacological activation of A1 adenosine and mGlu3 metabotropic glutamate receptors with N6-chlorocyclopentyladenosine (CCPA) and (-)2-oxa-4-aminocyclo-[3.1.0]hexane-4,6-dicarboxylic acid (LY379268), respectively, protects cultured astrocytes against apoptosis induced by a 3-hour exposure to oxygen/glucose deprivation (OGD). Protection by CCPA and LY379268 was less than additive and was abrogated by receptor blockade with selective competitive antagonists or pertussis toxin. Both in control astrocytes and in astrocytes exposed to OGD, CCPA and LY379268 induced a rapid activation of the phosphatidylinositol-3-kinase (PI3K) and extracellular signal-regulated kinases 1 and 2 (ERK1/2)/mitogen-activated protein kinase (MAPK) pathways, which are known to support cell survival. In cultures exposed to OGD, CCPA and LY379268 reduced the activation of c-Jun N-terminal kinase (JNK) and p38/MAPK, reduced the levels of the pro-apoptotic protein Bad, increased the levels of the anti-apoptotic protein Bcl-XL, and were highly protective against apoptotic death, as shown by nuclear DAPI staining and measurements of caspase 3 activity. All these effects were attenuated by treatment with U0126 and LY294002, which inhibit the MAPK and the PI3K pathways, respectively. These data suggest that pharmacological activation of A1 and mGlu3 receptors protects astrocytes against hypoxic/ischemic damage by stimulating the PI3K and ERK1/2 MAPK pathways.


Key words: Adenosine, Metabotropic glutamate, Gi family, MAP Kinase, Jun Kinase, P38 MAP Kinase, Signaling network analyses, Receptor-mediated, Apoptosis, Ischemia/Reperfusion





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics